Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum...
Clinical Trial
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"),...
FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued...
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the...
BeautyStat Daily Radiance Reviews: Don’t Buy Till You’ve Read This!
MIAMI, FL / ACCESS Newswire / December 31, 2025 / Dullness, uneven texture, dryness, and visible pores can disrupt confidence,...
MedMira Reports First Quarter Results FY2026
HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial...
KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
Cadrenal’s Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they see opportunity....
Zomedica Launches Next-Generation VETGuardian PLUS(TM) Monitor, Expanding Core Monitoring Platform in Growing Veterinary Market
New platform improves workflow efficiency, strengthens clinical confidence, and supports Zomedica's long-term growth strategy ANN ARBOR, MI / ACCESS Newswire...
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis...
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with...
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior,...
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on...
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing...
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer
GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility...
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of...
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those...
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as...